Colin N Haile1, Thomas R Kosten, Therese A Kosten. 1. Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, and Michael E DeBakey VA Medical Center, Houston, Texas 77030, USA.
Abstract
BACKGROUND: Pharmacogenetics uses genetic variation to predict individual differences in response to medications and holds much promise to improve treatment of addictive disorders. OBJECTIVES: To review how genetic variation affects responses to cocaine, amphetamine, and methamphetamine and how this information may guide pharmacotherapy. METHODS: We performed a cross-referenced literature search on pharmacogenetics, cocaine, amphetamine, and methamphetamine. RESULTS: We describe functional genetic variants for enzymes dopamine-beta-hydroxylase (DbetaH), catechol-O-methyltransferase (COMT), and dopamine transporter (DAT1), dopamine D4 receptor, and brain-derived neurotrophic factor (BDNF). A single nucleotide polymorphism (SNP; C-1021T) in the DbetaH gene is relevant to paranoia associated with disulfiram pharmacotherapy for cocaine addiction. Individuals with variable number tandem repeats (VNTR) of the SLC6A3 gene 3'-untranslated region polymorphism of DAT1 have altered responses to drugs. The 10/10 repeat respond poorly to methylphenidate pharmacotherapy and the 9/9 DAT1 variant show blunted euphoria and physiological response to amphetamine. COMT, D4 receptor, and BDNF polymorphisms are linked to methamphetamine abuse and psychosis. CONCLUSIONS: Disulfiram and methylphenidate pharmacotherapies for cocaine addiction are optimized by considering polymorphisms affecting DbetaH and DAT1 respectively. Altered subjective effects for amphetamine in DAT1 VNTR variants suggest a 'protected' phenotype. SCIENTIFIC SIGNIFICANCE: Pharmacogenetic-based treatments for psychostimulant addiction are critical for successful treatment.
BACKGROUND: Pharmacogenetics uses genetic variation to predict individual differences in response to medications and holds much promise to improve treatment of addictive disorders. OBJECTIVES: To review how genetic variation affects responses to cocaine, amphetamine, and methamphetamine and how this information may guide pharmacotherapy. METHODS: We performed a cross-referenced literature search on pharmacogenetics, cocaine, amphetamine, and methamphetamine. RESULTS: We describe functional genetic variants for enzymes dopamine-beta-hydroxylase (DbetaH), catechol-O-methyltransferase (COMT), and dopamine transporter (DAT1), dopamine D4 receptor, and brain-derived neurotrophic factor (BDNF). A single nucleotide polymorphism (SNP; C-1021T) in the DbetaH gene is relevant to paranoia associated with disulfiram pharmacotherapy for cocaine addiction. Individuals with variable number tandem repeats (VNTR) of the SLC6A3 gene 3'-untranslated region polymorphism of DAT1 have altered responses to drugs. The 10/10 repeat respond poorly to methylphenidate pharmacotherapy and the 9/9 DAT1 variant show blunted euphoria and physiological response to amphetamine. COMT, D4 receptor, and BDNF polymorphisms are linked to methamphetamine abuse and psychosis. CONCLUSIONS:Disulfiram and methylphenidate pharmacotherapies for cocaine addiction are optimized by considering polymorphisms affecting DbetaH and DAT1 respectively. Altered subjective effects for amphetamine in DAT1 VNTR variants suggest a 'protected' phenotype. SCIENTIFIC SIGNIFICANCE: Pharmacogenetic-based treatments for psychostimulant addiction are critical for successful treatment.
Authors: S T Weiss; A A Litonjua; C Lange; R Lazarus; S B Liggett; E R Bleecker; K G Tantisira Journal: Pharmacogenomics J Date: 2006-04-25 Impact factor: 3.550
Authors: N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; C Wong; J Logan Journal: Am J Psychiatry Date: 2001-03 Impact factor: 18.112
Authors: N D Volkow; G J Wang; J S Fowler; S J Gatley; Y S Ding; J Logan; S L Dewey; R Hitzemann; J Lieberman Journal: Proc Natl Acad Sci U S A Date: 1996-09-17 Impact factor: 11.205
Authors: I D Waldman; D C Rowe; A Abramowitz; S T Kozel; J H Mohr; S L Sherman; H H Cleveland; M L Sanders; J M Gard; C Stever Journal: Am J Hum Genet Date: 1998-12 Impact factor: 11.025
Authors: Rasmon Kalayasiri; Atapol Sughondhabirom; Ralitza Gueorguieva; Vladimir Coric; Wendy J Lynch; Peter T Morgan; Joseph F Cubells; Robert T Malison Journal: Pharmacol Biochem Behav Date: 2006-03-20 Impact factor: 3.533
Authors: R De La Garza; T F Newton; C N Haile; J H Yoon; C S Nerumalla; J J Mahoney; A Aziziyeh Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2011-12-30 Impact factor: 5.067
Authors: Richard M Kostrzewa; John P Kostrzewa; Rose Anna Kostrzewa; Florence P Kostrzewa; Ryszard Brus; Przemyslaw Nowak Journal: Neurotox Res Date: 2010-04-22 Impact factor: 3.911
Authors: David Smelson; Lei Yu; Steven Buyske; Gerardo Gonzalez; Jay Tischfield; Curtis K Deutsch; Douglas Ziedonis Journal: Am J Addict Date: 2012 Sep-Oct